Phosphodiesterase-5 inhibitors as novel cardioprotective agents: have we reached threshold for large-scale clinical trials?
We read with great interest the compelling findings of Andersson et al demonstrating strong association between on-demand use of phosphodiesterase-5 (PDE5) inhibitors (PDE5is) and a reduction in cardiovascular mortality and heart failure hospitalisation in patients followed up following their first myocardial infarction (MI). We previously reported in Heart a similarly strong association between PDE5i use and reduced mortality in a cohort of patients with type 2 diabetes and attendant high cardiovascular risk.
As the authors concede, and in similarity to our study, the observational nature of their work and the presence of unmeasured confounding factors (eg, marital status, physical activity, diposable income and educational attainment) make it impossible to establish concrete conclusions. Even so,...
Publisher URL: http://heart.bmj.com/cgi/content/short/103/21/1745
Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.
Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.